サログリタザール・マグネシウム市場：市場規模、予測、新たな洞察-2032年

サログリタザール・マグネシウムは米国で治験中の分子で、多嚢胞性卵巣症候群（PCOS）を伴うNAFLD、NASH、（PBC）などの肝疾患の治療薬として臨床評価中です。非臨床試験において、サログリタザール・マグネシウムは、PPARアルファおよびPPARガンマに関与するという独自のメカニズムにより、脂肪症、バルーン形成、炎症、線維化を含むNASHのすべての構成要素に良好な影響を及ぼすことが実証されています。

2021年5月、Zydus Therapeutics Inc.は、NASHおよび線維症を適応症とする被験者における有効性と安全性を評価するための第II相臨床試験（EVIDENCES-X試験）を開始する承認を米国FDAから取得しました。

当レポートでは、主要7ヶ国におけるサログリタザール・マグネシウム市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 非アルコール性脂肪肝炎（NASH）におけるサログリタザール・マグネシウムの概要

• 製品詳細
• 臨床開発
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 サログリタザール・マグネシウム市場評価

• 非アルコール性脂肪肝炎（NASH）におけるサログリタザール・マグネシウムの市場展望
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Saroglitazar Magnesium, Clinical Trial Description, 2023
• Table 2: Saroglitazar Magnesium, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Saroglitazar Magnesium Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Saroglitazar Magnesium Market Size in the US, in USD million (2019-2032)
• Table 7: Saroglitazar Magnesium Market Size in Germany, in USD million (2019-2032)
• Table 8: Saroglitazar Magnesium Market Size in France, in USD million (2019-2032)
• Table 9: Saroglitazar Magnesium Market Size in Italy, in USD million (2019-2032)
• Table 10: Saroglitazar Magnesium Market Size in Spain, in USD million (2019-2032)
• Table 11: Saroglitazar Magnesium Market Size in the UK, in USD million (2019-2032)
• Table 12: Saroglitazar Magnesium Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Saroglitazar Magnesium Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Saroglitazar Magnesium Market Size in the United States, USD million (2019-2032)
• Figure 3: Saroglitazar Magnesium Market Size in Germany, USD million (2019-2032)
• Figure 4: Saroglitazar Magnesium Market Size in France, USD million (2019-2032)
• Figure 5: Saroglitazar Magnesium Market Size in Italy, USD million (2019-2032)
• Figure 6: Saroglitazar Magnesium Market Size in Spain, USD million (2019-2032)
• Figure 7: Saroglitazar Magnesium Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Saroglitazar Magnesium Market Size in Japan, USD million (2019-2032)

"Saroglitazar Magnesium Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Saroglitazar Magnesium for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Saroglitazar Magnesium for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Saroglitazar Magnesium market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Saroglitazar Magnesium is an investigational molecule in the US, undergoing clinical evaluation to treat liver diseases like NAFLD with polycystic ovary syndrome (PCOS), NASH, and (PBC). Non-clinical studies have demonstrated that Saroglitazar Magnesium, due to its unique mechanism of engaging PPAR alpha and PPAR gamma, favorably affects all components of NASH, including steatosis, ballooning, inflammation, and fibrosis.

In May 2021, Zydus Therapeutics Inc. received approval from the US FDA to initiate Phase II clinical trials, viz EVIDENCES-X trials of the molecule to evaluate its efficacy and safety in subjects with NASH and fibrosis indications.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Saroglitazar Magnesium description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Saroglitazar Magnesium regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Saroglitazar Magnesium research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Saroglitazar Magnesium.
• The report contains forecasted sales of Saroglitazar Magnesium for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Saroglitazar Magnesium in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Saroglitazar Magnesium Analytical Perspective by DelveInsight

• In-depth Saroglitazar Magnesium Market Assessment

This report provides a detailed market assessment of Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Saroglitazar Magnesium Clinical Assessment

The report provides the clinical trials information of Saroglitazar Magnesium for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Saroglitazar Magnesium dominance.
• Other emerging products for NASH are expected to give tough market competition to Saroglitazar Magnesium and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Saroglitazar Magnesium in NASH.
• Our in-depth analysis of the forecasted sales data of Saroglitazar Magnesium from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Saroglitazar Magnesium in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Saroglitazar Magnesium?
• What is the clinical trial status of the study related to Saroglitazar Magnesium in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Saroglitazar Magnesium development?
• What are the key designations that have been granted to Saroglitazar Magnesium for NASH?
• What is the forecasted market scenario of Saroglitazar Magnesium for NASH?
• What are the forecasted sales of Saroglitazar Magnesium in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Saroglitazar Magnesium for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Saroglitazar Magnesium Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Saroglitazar Magnesium Market Assessment

• 5.1. Market Outlook of Saroglitazar Magnesium in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Saroglitazar Magnesium in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Saroglitazar Magnesium in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Saroglitazar Magnesium in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Saroglitazar Magnesium in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Saroglitazar Magnesium in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Saroglitazar Magnesium in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Saroglitazar Magnesium in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Saroglitazar Magnesium in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options